ODACTRA is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites or by positive skin testing to licensed house dust mite allergen extracts.
Merck announced that the FDA has accepted for review the Biologics License Application (BLA) for MK-8237, Merck’s house dust mite...
Merck has submitted a Biologics License Application (BLA) to the FDA for its house dust mite (HDM) sublingual allergy immunotherapy...
ALK has announced that its house dust mite sublingual allergy immunotherapy (SLIT) tablet Acarizax has had its approval in 12...
ALK has obtained European approval for its HDM-SLIT (house dust mite sublingual allergy immunotherapy tablet) against allergic rhinitis and allergic...
Circassia Pharmaceuticals plc announces top-line results from its investigational house dust mite allergy immunotherapy phase IIb field study. In the...
Altamira Therapeutics Ltd. announced the publication of the detailed results from its clinical trial with Bentrio nasal spray in house dust mite (“HDM”) allergic rhinitis
ALK has announced that The Journal of the American Medical Association (JAMA) has published results from a Phase III clinical...
ALK Abello announced positive top-line results from the pivotal Phase III MITRA trial conducted with the allergy immunotherapy tablet against...
ALK has presented trial results on Mitizax (sublingual allergy immunotherapy tablet or SLIT-tablet) for House Dust Mite (HDM) respiratory Allergic...